/PRNewswire/ DLBCL is a cancer of B-lymphocytes and is the most common type of Non-Hodgkins Lymphoma (NHL) among adults. It is a fast-growing and complex.
Share:
Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced the appointment of Nakaya Nick Matsumaru as General Manager of its new clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan.
SOMERSET, N.J. (PRWEB) December 10, 2020 Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced the appointment of Nakaya Nick Matsumaru as General Manager of its new clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan.